Information de base

Numéro de Référence

00002169998

Organisation émettrice

University of British Columbia

Type d’appel d’offres

DDP - Demande de proposition (Formel)

Numéro d’appel d’offres

2019010444

Titre

Clinical Phase II/III Trial of Ustekinumab to treat type 1 diabetes

Code d’identité d’origine

SCRIBE

Détails

Emplacement

Colombie Britannique

Type d’achat

Non-mentionné

Dates

Publication

2020-05-11 16h00:00 HAE

Date de fermeture

2020-05-28 17h00:00 HAE

Information du contact

Hassan, Mohammed

mohammed.hassan@ubc.ca

Description

REQUEST FOR PROPOSAL (RFP) 2019010444 TITLE: Clinical Phase II/III Trial of Ustekinumab to treat type 1 diabetes (UST1D2).

UBC requires the following services:
This is a multi-site randomized placebo-controlled clinical study of ustekinumab in recent onset type 1 diabetes requiring clinical monitoring and operations oversight services. Duration of the trial from first Patient First visit to Last Patient Last Visit is anticipated to be three years. Start date dependent on restrictions lifted. Remote and on-site clinical monitoring services are requested to ensure participant safety, and the quality and integrity of the data collected in sponsored clinical trials are in accordance with the approved protocol, SOPs, ICH/GCP and regulatory requirements.

Afficher davantage

Dérogation All amendments to the associated notice, including amended documents, plans and specifications (where applicable), are issued on bcbid.gov.bc.ca. MERX asks that you refer to bcbid.gov.bc.ca notice for these amendments. MERX stipulates that potential bidders may also be required to register with the buying authority as a bidder/plan taker. The contact information can be found within the notice abstract.